What’s Trending?

Yet another Teva exec is heading out the door, and at least one analyst has some concerns about his departure. [...]
Fri, Dec 15, 2017
Source FiercePharma
Merck's Keytruda boasts an FDA approval in third-line stomach cancer, but its ambitions for moving earlier into treatment just took a hit. [...]
Fri, Dec 15, 2017
Source FiercePharma
Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread. [...]
Fri, Dec 15, 2017
Source FiercePharma
For the second straight week, there's a new psoriatic arthritis drug on the block. This week, that drug is Pfizer's Xeljanz, which nabbed an FDA approval late Thursday to treat patients who haven't adequately responded to or are intolerant of methotrexate or other disease-modifying medications. [...]
Fri, Dec 15, 2017
Source FiercePharma
Around one in 3,300 children in Germany is born with Mucoviscidosis. A characteristic of this illness is that one channel albumen on the cell surface is disturbed by mutations. Thus, the amount of water of different secretions in the body is reduced which creates a tough mucus. As a consequence, [...]
Fri, Dec 15, 2017
Source WorldPharmaNews
The 2018 competition is well underway. Hundreds of competitors have completed Stage 1, a multiple-choice questionnaire testing knowledge of Good Clinical Practice. [...]
Fri, Dec 15, 2017
Source PharmaTimes
Pfizer
Pfizer Inc. (NYSE:PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product. [...]
Fri, Dec 15, 2017
Source WorldPharmaNews
The deadline for entry to the prestigious PharmaTimes International Clinical Researcher of the Year 2018 is 31 January, so don't delay, head over to the website today to register your details and get started on the Multiple-Choice Questionnaire. [...]
Fri, Dec 15, 2017
Source PharmaTimes
It is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen's Imbruvica on the NHS. [...]
Thu, Dec 14, 2017
Source PharmaTimes
Shire, the Royal College of Surgeons Ireland (RCSI) and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, have initiated a new study that aims to better personalise the care of haemophilia patients. [...]
Thu, Dec 14, 2017
Source PharmaTimes
Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, resulting in reduced weight loss after virus infection and lower amounts of virus replication in the lungs, according to a study led by Georgia State University. Influenza virus can [...]
Thu, Dec 14, 2017
Source WorldPharmaNews
A 'cure' for haemophilia is one step closer, following results published in the New England Journal of Medcine of a groundbreaking gene therapy trial led by the NHS in London. Clinical researchers at Barts Health NHS Trust and Queen Mary University of London have found that over one year on [...]
Thu, Dec 14, 2017
Source WorldPharmaNews
Thu, Nov 16, 2017
Source FDANews
An Alzheimer's research group offers positive news on clinical trials for Alzheimer's drugs as well as suggestions for the way forward, in a new report. [...]
Thu, Nov 16, 2017
Source FDANews
The FDA warned investigational medical device sponsor UVLrx Therapeutics for failing to obtain required authorization from its Institutional Review Board. [...]
Thu, Nov 16, 2017
Source FDANews
In a significant policy shift, China plans to accept data from foreign clinical trials in its drug approval process if the drug is already approved overseas. [...]
Thu, Nov 16, 2017
Source FDANews